NIH Could Get Royalties, Not Input On Pricing, From R&D Investments, Collins Says
Executive Summary
Federal funding for research and development of drugs can garner royalties for the U.S. Treasury but does not provide leverage to affect pricing decisions, National Institutes of Health Director Francis Collins told a Senate appropriations subcommittee May 11.
You may also be interested in...
Collins Promises To Send NCATS Funding Proposal To Congress Within Weeks
National Institutes of Health Director Francis Collins expects to send, "in the fairly near future," detailed plans to Congress for shifting existing translational research projects into a new National Center for Advancing Translational Research.
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
FDA is citing patient access as the reason behind its unusual decision to insert itself in the middle of a pricing debate involving KV Pharmaceuticals’ pre-term delivery drug Makena.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.